Abstract

Thousands of biotech companies are developing promising products, but have insufficient resources to complete the clinical testing process, while large, well-funded companies have increasingly focused on the need to access external innovation. As a result, licensing deals are an essential and growing part of this industry. Yet, casting a shadow over the licensing market is the classic Lemons Problem: Does asymmetrical information put licensees at a severe disadvantage, leading to a market dominated by inferior opportunities, with the best products retained for internal development? Our analysis of clinical stage products developed over three decades shows that there is no Lemons Problem. We discuss the results of this first apples-to-apples analysis of the biomedical licensing market, and suggest reasons why the Lemons Problem does not exist where it might be most expected—in a high technology, knowledge-based industry.

Highlights

  • Multi-billion dollar investments and high failure rates are “business as usual” for the biopharmaceutical industry (DiMasi et al, 2016)

  • Casting a shadow over this lively licensing market is the classic Lemons Problem identified by Nobel laureate George Akerlof: Will the licensors’ superior knowledge about the products put licensees at a severe disadvantage, leading to a market dominated by inferior opportunities, with the best products retained for internal development?

  • We will discuss the results of this first apples-to-apples analysis of the biomedical licensing market, and suggest reasons why the Lemons Problem, a phenomenon taught to every first-year MBA student, does not exist where it might be most expected—in a high technology, knowledge-based industry

Read more

Summary

Introduction

Multi-billion dollar investments and high failure rates are “business as usual” for the biopharmaceutical industry (DiMasi et al, 2016). Our analysis of all clinical stage products developed over three decades by the most prominent biotechnology companies shows that there is no Lemons Problem in biopharmaceutical licensing.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call